ClinicalTrials.gg
CompletedNCT02054286Updated Apr 11, 2019

Safety, Tolerability and Immunogenicity Induced by the THV01 Treatment in Patients Infected With HIV-1 Clade B and Treated With Highly Active Antiretroviral Therapy (HAART).

A Phase 1/2 interventional study of THV01-1 and THV01-2 in HIV Infection, sponsored by Theravectys S.A.. Completed at 11 sites in 2 countries. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2019-04-11.

Sponsored by Theravectys S.A. · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 1 year 2 months after the study started (first participant enrolled Dec 2012, registered Feb 2014).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
38
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 278 studies in HIV Infections with a site in France — 19 open to participants now, 27 under way, 5 of them phase 3. HIV Infections · France.

Enrollment
183rd of 213
38 · median 186
Started
2012
with 5 others
Phase 1/2
7 of 278
none open now
Registered
181st of 278
by date

Among the 278 studies in HIV Infections with a site in France, this one is the 183rd largest by enrollment of the 213 interventional ones that give a count, is one of 6 that started in 2012, is one of 7 in phase 1/2, and was the 181st registered.

HIV Infections

4,737 studies on the registry are indexed under HIV Infections; 247 are open to participants now.

Browse HIV Infections studies →

Open to participants now

19 of the 278 studies in HIV Infections with a site in France are open now. Recruiting first, the newest first:

14 more — sign in →

All 19 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 278 studies in HIV Infections with a site in France, or all of them as a file.
02

Study summary

The objectives of this Phase I/II trial is to evaluate the safety, tolerability and immunogenicity of THV01 compared to placebo in HIV-1 infected patients on HAART (highly active antiretroviral therapies).

THV01 is composed of two vaccines that derived from the HIV (human immunodeficiency virus): lentiviral vectors. They are non-replicative and not infectious. They will be injected intramuscularly, eight weeks apart. Three doses will be assessed and compared to placebo.

Eligible patients must have an undetectable viral load and must be treated by HAART for more than 12 months. They will be randomly allocated to one of the study group and will receive the experimental drugs at one of the three doses or a matching placebo.

Their anti-HIV treatment will be alleviated around each experimental drugs' administration to enable THV01 efficacy. HAART will be resumed one week after the second injection. 15 weeks after resumption, HAART will be interrupted. Patients will then be monitored every 2 weeks for CD4+ T cell counts and viral load as well as for thorough assessment of the elicited immune response. Stringent anti-HIV treatments resumption criteria have been implemented, based on the CD4+ T cell counts and the viral load.

38 patients were enrolled in THV01-11-01 study and received the 2 injections.

A long-term follow-up of all enrolled patients will be performed for 5 years post-prime administration. This will provide additional data on the safety and the potential long-term risks/benefits associated with THV01.

The final study report will be written after the last patient last visit in the long-term follow-up.

Read the detailed description

This Phase I/II is a randomized, double-blind and placebo controlled study to assess safety, tolerability and immunogenicity of THV01 at three doses in patients infected with the HIV-1 clade B currently on HAART (highly active antiretroviral therapies).

THV01 involves two intramuscular injections, consisting of the THV01-1 and THV01-2 lentiviral vectors, to be administered intramuscularly eight weeks apart. These lentiviral vectors are non-replicative and self-inactivating. Both encode the same HIV antigen.

36 patients were planned to be enrolled. They must be HIV-1 (clade B) infected patients, treated by HAART for more than 12 months and with an undetectable viral load.

Patients will be randomly allocated to one of the groups:

  • Group 1: patients will receive the THV01-1 and THV01-2 vaccines at 5.10E+6 TU (transducing unit) or placebo;
  • Group 2: patients will receive the THV01-1 and THV01-2 vaccines at 5.10E+7 TU (transducing unit) or placebo;
  • Group 3: patients will receive the THV01-1 and THV01-2 vaccines at 5.10E+8 TU (transducing unit) or placebo.

Hence, twelve patients will be randomized in blocks of 4 in a 3:1 ratio (vaccine:placebo) for each dose.

Experimental drugs' injection will occur at Week 0 and Week 8. HAART will be alleviated for all patients during this "vaccination phase" to enable efficient transduction of the host cells by the lentiviral vectors. Initial HAART will be resumed at Week 9.

Starting on Week 24, HAART will be interrupted. Patients will then be monitored on a very stringent rhythm. HAART resumption criteria based on the CD4+ T cell counts and the viral load have been implemented to guaranty safety of all enrolled patients.

38 patients were enrolled in THV01-11-01 study and received the 2 injections.

A long-term follow-up of all enrolled patients will be performed for 5 years after the administration of THV01-1. During this follow-up, three visits are planned per year, during which blood will be sampled. This will provide data on the long-term safety of THV01 and the potential long-term risks/benefits associated with THV01.

03

Conditions studied

  • HIV Infection

Browse trials for

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients infected with clade B -1;
  • Confirmation of a Gag clade B genotyping performed at screening;
  • Patient must be treated by a triple agents therapy for more than 12 months at baseline: this triple agents therapy should encompasses two (2) nucleosidic reverse transcriptase inhibitors plus one (1) boosted protease inhibitor, or two (2) nucleosidic reverse transcriptase inhibitors plus one (1) non nucleosidic reverse transcriptase inhibitor;
  • Patients must be treated for more than 60 days at baseline by two (2) nucleosidic reverse transcriptase inhibitors plus a ritonavir boosted protease inhibitor treatment among darunavir+ritonavir or lopinavir+ritonavir;
  • Patients' HIV plasma viral load ≤150,000 copies mL-1 at any monitoring time (apart measurement during primo-infection if recorded);
  • Patients with HIV plasma viral load persistently ≤ 50 copies mL-1 during the 12 months prior to screening;
  • Patients' ≥ 300 cells per mm3 at any time since diagnosis;
  • Patient's CD4+ T cells count \< 500 cells per mm3 at least once from diagnosis to initiation of antiretroviral treatment;
  • Patients with CD4+ T cells count ≥ 600 cells per mm3 at baseline;
  • Man or woman aged 18-55 years;

Exclusion criteria

Exclusion Criteria

  • -2 infection;
  • Patient treated by HIV entry of fusion inhibitors;
  • Patient treated by HIV integrase inhibitors;
  • Patient displaying any HIV protease inhibitor resistance mutation as listed in the current version of the HIV drug resistance database (Stanford University);
  • Patient having undergone virological failure as defined by a viral load ≥ 500 copies mL-1 confirmed by a second measure, since initiation of treatment;
  • More than 2 blips with viral load comprised between 50 and 500 copies mL-1 during the 12 months prior inclusion;
  • History of an AIDS-defining clinical illness;
  • Concomitant AIDS-related opportunistic disease;
  • History of allergic disease, anaphylaxis or reactions likely to be triggered or exacerbated by any component of the vaccine such as lactose;
  • Acute or chronic infectious disease other than AIDS (include but not limited to viral hepatitis such as and , active tuberculosis, active syphilis, HTLV-1, HTLV-2);
  • Acute, chronic or history of pulmonary, cardiovascular, gastrointestinal, hepatic, pancreatic or renal functional abnormality, encephalopathy, neuropathy or unstable CNS pathology, angina or cardiac arrhythmias, or any other clinically significant medical problems as determined by physical examination and/or laboratory screening tests and/or medical history;
  • Severe hepatic impairment;
  • Serious dyslipidaemia;
  • Severe disorders of blood coagulation;
  • Known or suspected allergy to egg phospholipids, soy proteins and/or peanut;
  • Acute, chronic or history of immunodeficiency or disease other than HIV infection;
  • Unstable asthma (defined as sudden acute attacks occurring in less than three hours without an obvious trigger, hospitalisation for asthma in the last two years); food or wine induced asthma;
  • History of unless there has been surgical excision that is considered to have achieved cure;
  • Active malignancy that may require chemotherapy or radiation therapy;
  • Seizure disorder or any history of prior seizure;
  • Subjects planning to receive a prophylactic or therapeutic vaccination during the study except Influenza immunization;
  • Subjects who have received any vaccination for the 3 months prior the first injection;
  • Subjects having an infective exacerbation as defined as a requirement of inhaled, oral, or intravenous antibiotics at W-2 or later;
  • Serious illness requiring systemic treatment and/or hospitalization within 7 days prior to baseline;
  • Pregnant or breast-feeding woman;
  • Any of intramuscular injection;
  • Active drug or alcohol abuse or dependence;
  • Any condition, which in the opinion of the investigator, could compromise the subject's safety or adherence to the study protocol.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
38 participants (actual)

Study arms

  • Experimental
    Group 1: THV01 (5.10E+6 TU) or Placebo

    5.10E+6 TU (transducing unit) of THV01-1 (Week 0) OR matching placebo; 5.10E+6 TU (transducing unit) of THV01-2 (Week 8) OR matching placebo

    Biological: THV01-1 · Biological: THV01-2 · Biological: Placebo

  • Experimental
    Group 2: THV01 (5.10E+7 TU) or Placebo

    5.10E+7 TU (transducing unit) of THV01-1 (Week 0) OR matching placebo; 5.10E+7 TU (transducing unit) of THV01-2 (Week 8) OR matching placebo

    Biological: THV01-1 · Biological: THV01-2 · Biological: Placebo

  • Experimental
    Group 3: THV01 (5.10E+8 TU) or Placebo

    5.10E+8 TU (transducing unit) of THV01-1 (Week 0) OR matching placebo; 5.10E+8 TU (transducing unit) of THV01-2 (Week 8) OR matching placebo

    Biological: THV01-1 · Biological: THV01-2 · Biological: Placebo

Interventions

  • BiologicalTHV01-1

    Intramuscular injection of THV01-1 (week 0)

    Also known as: lentiviral vector ancoding an HIV antigen

  • BiologicalTHV01-2

    Intramuscular injection of THV01-2 (week 8)

    Also known as: lentiviral vector encoding an HIV antigen

  • BiologicalPlacebo

    Intramuscular injection of placebo matching THV01-1 and THV01-2

    Also known as: Placebo matching THV01-1 and THV01-2

06

What researchers measure

Primary outcomes

  1. Safety and tolerability

    Occurrence of at least one grade 3 or higher adverse event including signs/symptoms, laboratory toxicities and/or clinical events possibly, probably or definitely related to study treatment.

    Time frame: From Week 0 to Week 24

Secondary outcomes

  1. Safety and tolerability

    Occurrence of at least one grade 3 or higher adverse event including signs/symptoms, laboratory toxicities and/or clinical events possibly, probably or definitely related to study treatment.

    Time frame: From baseline to Week 88 (or early termination).

  2. Immunogenicity

    Monitoring the cellular immune response by treatment group versus placebo.

    Time frame: From baseline to Week 88 (or early termination).

Other outcomes

  1. HIV reservoir (HIV total DNA)

    Evaluation of HIV reservoir by treatment group versus placebo.

    Time frame: From baseline to five years after the prime injection.

  2. Long term safety

    Occurrence of any SAE (serious adverse event) suspected to be related to IMP.

    Time frame: From Week 88 to five years after the prime injection.

07

Study locations

11 sites
  • CHU Saint-Pierre
    Bruxelles, B-1000, Belgium
  • CHU Liège
    Liège, B-4000, Belgium
  • CHU Clermont-Ferrand
    Clermont-Ferrand, 65003, France
  • CHU Dijon
    Dijon, 21079, France
  • CHU Croix-Rousse
    Lyon, 69317, France
  • Hôpital Saint-Louis
    Paris, 75010, France
  • CIC Cochin-Pasteur; Hôpital Cochin
    Paris, 75014, France
  • CHU Rennes
    Rennes, 35033, France
  • Hôpital Nord
    Saint-Etienne, 42055, France
  • CHU Strasbourg
    Strasbourg, 6091, France
  • Hôpital Purpan
    Toulouse, 31059, France
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2012 to primary completion in Aug 2014, 20 months.

Of 42 phase 1/2 interventional studies under HIV Infections, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 73. This study's 20 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 1, 2014
First posted
Feb 4, 2014
StartActual
Dec 2012
Primary completionActual
Aug 2014
CompletionActual
Feb 27, 2019
Last update
Apr 11, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 11, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02054286
Lead sponsor
Theravectys S.A.
Responsible party
Sponsor
First posted
Feb 4, 2014
Start date
Dec 2012
Primary completion
Aug 2014
Completion
Feb 27, 2019
Last update
Apr 11, 2019

Study contacts

Odile Launay, Pr
principal investigator · CIC Cochin-Pasteur; Hôpital Cochin; Paris

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion